Related Experiment Video
Updated: Jul 18, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
Marino Paroli1, Andrea Becciolini2, Elena Bravi3
1Department of Clinical, Internist, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Medicina (Kaunas, Lithuania)
|August 26, 2023
Summary
Tofacitinib (TOFA) shows a good retention rate in rheumatoid arthritis (RA) patients over 48 months in real-world clinical practice. This Janus kinase inhibitor (JAKi) is a viable treatment option for RA patients who have not responded to other therapies.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Tofacitinib (TOFA) is the first Janus kinase inhibitor (JAKi) approved for rheumatoid arthritis (RA).
- Definitive data on TOFA therapy retention rates in real-world settings are still limited.
- This study aims to provide new real-world data on TOFA retention over an extended period.
Purpose of the Study:
- To evaluate the long-term retention rate of Tofacitinib (TOFA) in a cohort of rheumatoid arthritis (RA) patients.
- To assess factors influencing TOFA discontinuation in a real-world clinical setting.
Main Methods:
- A multicenter retrospective study involving 213 RA patients from 23 Italian rheumatology centers.
- Patients were treated with TOFA monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
- Kaplan-Meier method assessed TOFA retention rates up to 48 months; Cox regression analyzed discontinuation predictors.
Main Results:
- TOFA retention rates were 86.5% at 12 months, 78.8% at 24 months, 63.8% at 36 months, and 59.9% at 48 months.
- No analyzed factors (previous treatments, disease activity, demographics, comorbidities) predicted TOFA retention.
- Safety data were consistent with findings from registration studies.
Conclusions:
- Tofacitinib (TOFA) demonstrates a favorable long-term retention rate in rheumatoid arthritis (RA) patients in real-world practice.
- TOFA is a viable treatment alternative for RA patients who have failed csDMARDs and/or biologic DMARDs (bDMARDs).
- Further large-scale, long-term observational studies are needed to validate these findings.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
01:19Pharmacovigilance
889
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
889
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173